Literature DB >> 9444958

Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.

A Bardelli1, P Longati, D Gramaglia, M C Stella, P M Comoglio.   

Abstract

Activation of the HGF receptor, encoded by the c-MET protooncogene (Met receptor), triggers motility, matrix-invasion and branching morphogenesis in epithelial cells. It has recently been shown that the Met receptor interacts with Gab-1, an IRS-like adaptor protein, via the docking site (Y1349VHVNATY1356VNV) known to bind Grb2 and multiple SH2-containing signal transducers. Here we show that Gab1 is the major phosphorylation-substrate of the Met receptor and of its oncogenic variant Tpr-Met. A series of point mutations in the docking site established a direct correlation between the ability to recruit and phosphorylate Gab1 and the transforming potential. Interestingly, the mutations of either Y1356 or N1358 abolished the binding of both Grb2 and Gab1 in intact cells. Furthermore, peptides designed to block either the SH2 or the SH3 domains of Grb2 interfered with the receptor-Gab1 interaction. These data indicate that Gab1 coupling to the Met receptor requires binding of Grb2 and correlates with the transforming potential of Tpr-Met.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444958     DOI: 10.1038/sj.onc.1201561

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M Holgado-Madruga; I Royal; M A Naujokas; T M Fournier; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

3.  ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen.

Authors:  P R Nicholson; S Empereur; H R Glover; S M Dilworth
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

4.  Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.

Authors:  Lisa S Lock; Christiane R Maroun; Monica A Naujokas; Morag Park
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

5.  [Molecular mechanisms of progression in human hepatocarcinogenesis].

Authors:  K Breuhahn
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

6.  Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Authors:  Angelina Felici; Alessio Giubellino; Donald P Bottaro
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

7.  Annexin II binds to SHP2 and this interaction is regulated by HSP70 levels.

Authors:  Jae Cheal Yoo; Michael J Hayman
Journal:  Biochem Biophys Res Commun       Date:  2007-03-19       Impact factor: 3.575

Review 8.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

9.  Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET.

Authors:  Amitabha Chaudhuri; Ming-Hong Xie; Becky Yang; Kaushiki Mahapatra; Jinfeng Liu; Scot Marsters; Sweta Bodepudi; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

10.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Authors:  A Bardelli; P Longati; D Gramaglia; C Basilico; L Tamagnone; S Giordano; D Ballinari; P Michieli; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.